Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
In the Pharmaceuticals & Drugs sector, Ishita Drugs & Industries Ltd. stands out for its unique position with no revenue or profit metrics reported, contrasting sharply with its peers who demonstrate varying degrees of financial performance and valuation. While some companies showcase strong profitability and growth, Ishita appears financially weak, suggesting a potential risk for investors. Companies like Sun Pharmaceutical and Dr. Reddy's display strong performance metrics, indicating they are sector leaders, while Ishita may need to improve its financial health to remain competitive.
Highest revenue growth of 8.42% YoY, strong EPS growth, and ROE of 16.13%.
High profitability with a PE ratio of 15.50 and strong growth metrics.